CDK4/6和Bcl-2的双重靶向对套细胞淋巴瘤显示出强大的抗肿瘤作用。 - Suppr

Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.

作者信息

Che Yuxuan, Liu Yang, Li Yijing, McIntosh Joseph M, Jordan Alexa, Yan Fangfang, Wang Wei, Nie Lei, Lee Heng-Huan, Jin Jingling, Yao Yixin, Zhao Zhongming, Jiang Vivian Changying, Wang Michael

机构信息

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX.

出版信息

Blood Adv. 2023 Jul 25;7(14):3361-3365. doi: 10.1182/bloodadvances.2022008954.

DOI:10.1182/bloodadvances.2022008954

PMID:37257192

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10345850/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79ab/10345850/f1e5bc51030e/BLOODA_ADV-2022-008954-gr1.jpg

相似文献

Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.

Blood Adv. 2023 Jul 25;7(14):3361-3365. doi: 10.1182/bloodadvances.2022008954.

Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Hematol Oncol Clin North Am. 2020 Oct;34(5):809-823. doi: 10.1016/j.hoc.2020.05.003. Epub 2020 Aug 1.

Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.

Leukemia. 2016 Jan;30(1):86-93. doi: 10.1038/leu.2015.185. Epub 2015 Jul 15.

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Blood. 2015 Sep 24;126(13):1565-74. doi: 10.1182/blood-2015-04-639542. Epub 2015 Aug 7.

A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.

Am J Pathol. 2012 Apr;180(4):1688-701. doi: 10.1016/j.ajpath.2012.01.004. Epub 2012 Feb 9.

P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Mol Cancer. 2012 Oct 18;11:77. doi: 10.1186/1476-4598-11-77.

A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.

Leuk Lymphoma. 2019 May;60(5):1214-1223. doi: 10.1080/10428194.2018.1520986. Epub 2018 Nov 14.

Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.

Cancer Res. 2005 Jan 15;65(2):587-95.

ZGDHu-1 promotes apoptosis of mantle cell lymphoma cells.

Oncotarget. 2017 Feb 14;8(7):11659-11675. doi: 10.18632/oncotarget.14274.

Bryostatin analogue-induced apoptosis in mantle cell lymphoma cell lines.

Exp Hematol. 2012 Aug;40(8):646-56.e2. doi: 10.1016/j.exphem.2012.03.002. Epub 2012 Mar 28.

引用本文的文献

Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation.

BMC Cancer. 2024 Apr 8;24(1):432. doi: 10.1186/s12885-024-12166-0.

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.

Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2.

本文引用的文献

PIK-75 overcomes venetoclax resistance blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.

Am J Cancer Res. 2022 Mar 15;12(3):1102-1115. eCollection 2022.

WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation.

Cell Death Dis. 2020 Jul 16;11(7):537. doi: 10.1038/s41419-020-02752-y.

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study.

Haematologica. 2021 Mar 1;106(3):859-862. doi: 10.3324/haematol.2019.224535.

Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.

Mol Cancer Ther. 2019 Feb;18(2):267-277. doi: 10.1158/1535-7163.MCT-18-0478. Epub 2018 Nov 9.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

Mammalian HspB1 (Hsp27) is a molecular sensor linked to the physiology and environment of the cell.

Cell Stress Chaperones. 2017 Jul;22(4):517-529. doi: 10.1007/s12192-017-0765-1. Epub 2017 Jan 31.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.

Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13.

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.

Sci Rep. 2014 Jan 6;4:3574. doi: 10.1038/srep03574.

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Blood. 2011 Jan 6;117(1):26-38. doi: 10.1182/blood-2010-04-189977. Epub 2010 Oct 12.

Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Blood. 2009 Mar 26;113(13):3059-69. doi: 10.1182/blood-2008-07-170183. Epub 2008 Nov 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.

作者信息

Che Yuxuan, Liu Yang, Li Yijing, McIntosh Joseph M, Jordan Alexa, Yan Fangfang, Wang Wei, Nie Lei, Lee Heng-Huan, Jin Jingling, Yao Yixin, Zhao Zhongming, Jiang Vivian Changying, Wang Michael

机构信息

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX.

出版信息

Blood Adv. 2023 Jul 25;7(14):3361-3365. doi: 10.1182/bloodadvances.2022008954.

DOI:10.1182/bloodadvances.2022008954

PMID:37257192

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10345850/

Abstract

摘要

相似文献

Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.

Blood Adv. 2023 Jul 25;7(14):3361-3365. doi: 10.1182/bloodadvances.2022008954.

Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Hematol Oncol Clin North Am. 2020 Oct;34(5):809-823. doi: 10.1016/j.hoc.2020.05.003. Epub 2020 Aug 1.

Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.

Leukemia. 2016 Jan;30(1):86-93. doi: 10.1038/leu.2015.185. Epub 2015 Jul 15.

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Blood. 2015 Sep 24;126(13):1565-74. doi: 10.1182/blood-2015-04-639542. Epub 2015 Aug 7.

A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.

Am J Pathol. 2012 Apr;180(4):1688-701. doi: 10.1016/j.ajpath.2012.01.004. Epub 2012 Feb 9.

P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Mol Cancer. 2012 Oct 18;11:77. doi: 10.1186/1476-4598-11-77.

A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.

Leuk Lymphoma. 2019 May;60(5):1214-1223. doi: 10.1080/10428194.2018.1520986. Epub 2018 Nov 14.

Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.

Cancer Res. 2005 Jan 15;65(2):587-95.

ZGDHu-1 promotes apoptosis of mantle cell lymphoma cells.

Oncotarget. 2017 Feb 14;8(7):11659-11675. doi: 10.18632/oncotarget.14274.

Bryostatin analogue-induced apoptosis in mantle cell lymphoma cell lines.

Exp Hematol. 2012 Aug;40(8):646-56.e2. doi: 10.1016/j.exphem.2012.03.002. Epub 2012 Mar 28.

引用本文的文献

Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation.

BMC Cancer. 2024 Apr 8;24(1):432. doi: 10.1186/s12885-024-12166-0.

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.

Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2.

本文引用的文献

PIK-75 overcomes venetoclax resistance blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.

Am J Cancer Res. 2022 Mar 15;12(3):1102-1115. eCollection 2022.

WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation.

Cell Death Dis. 2020 Jul 16;11(7):537. doi: 10.1038/s41419-020-02752-y.

Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study.

Haematologica. 2021 Mar 1;106(3):859-862. doi: 10.3324/haematol.2019.224535.

Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.

Mol Cancer Ther. 2019 Feb;18(2):267-277. doi: 10.1158/1535-7163.MCT-18-0478. Epub 2018 Nov 9.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

Mammalian HspB1 (Hsp27) is a molecular sensor linked to the physiology and environment of the cell.

Cell Stress Chaperones. 2017 Jul;22(4):517-529. doi: 10.1007/s12192-017-0765-1. Epub 2017 Jan 31.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.

Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13.

HE4 (WFDC2) gene overexpression promotes ovarian tumor growth.

Sci Rep. 2014 Jan 6;4:3574. doi: 10.1038/srep03574.

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Blood. 2011 Jan 6;117(1):26-38. doi: 10.1182/blood-2010-04-189977. Epub 2010 Oct 12.

Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.

Blood. 2009 Mar 26;113(13):3059-69. doi: 10.1182/blood-2008-07-170183. Epub 2008 Nov 4.

Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献